StockData
NewcelX Ltd. logo

NewcelX Ltd. (NCEL) stock

NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 4/30
$2.54−0.15 (-5.58%)

Close on Nov 20, 2026Market cap $12.19MP/E 1.2Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$12.19M
P/E ratio
1.2
Price to sales
–
Price to book
2.02
Dividend yield
–
Free cash flow yield
-22.76%

Fundamentals

Net income
-$8.30M
EPS, diluted
$2.16
Free cash flow
-$2.77M

Trading

Previous close
$2.69
Open
$2.63
Day's range
$2.45 – $2.63
Volume
5,727
Average volume (20 days)
26,993
Beta (5 years)
0.83
52-week range
$1.83 – $5.12
RSI (14 days)
43.4
Volatility (1 year)
101.5%
Relative volume
0.44×
WACC
9.2%

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.

PeriodNCELS&P 500DifferenceNCEL per yearS&P 500 per year
1 month-2.7%-10.3%+7.6 pts
3 months-24.6%-9.3%−15.3 pts
Year to date+33.7%+1.9%+31.7 pts
1 year-19.4%+6.9%−26.2 pts
3 years-98.6%+57.5%−156.0 pts-75.7%+16.3%
5 years-99.7%+57.3%−157.0 pts-68.2%+9.5%

Nine years at a glance

Fiscal years 2017 to 2025, USD

Operating income

-$2.56M

Net income

-$8.30M

EPS, diluted

$2.16-11.1% YoY

Free cash flow

-$2.77M
Reported period

Press releases

Releases NewcelX filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About NewcelX

Pharmaceutical Preparations

NewcelX Ltd. is a clinical-stage biopharmaceutical enterprise specializing in the development and manufacture of proprietary, allogeneic, off-the-shelf cell therapy products. Utilizing a proprietary technology platform designed for expanding and differentiating human embryonic stem cells (hESCs) into functional cells, the firm advances regenerative medicine candidates. Its clinical-stage pipeline features therapeutic programs such as NCEL-101 and AstroRx. Because its candidates remain in the clinical development and evaluation phases, the company does not yet market commercial products or generate commercial revenue, aiming ultimately to serve patients and healthcare providers through clinical collaborations and specialized medical partnerships.

Company profile, executives and history

NewcelX stock: common questions

What is NewcelX's stock price?

NCEL closed at $2.54 on Nov 20, 2026, down 5.58% on the day. Over the past 52 weeks it traded between $1.83 and $5.12.

What is NewcelX's market cap?

NewcelX was worth $12.19M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.

What is NCEL's P/E ratio?

NCEL trades at 1.2 times earnings, based on diluted earnings per share of $2.16 over fiscal 2025.

Does NewcelX pay a dividend?

No. NewcelX has not paid a cash dividend over the last twelve months.

How has NCEL stock performed over the past year?

Including dividends, NCEL returned -19.4% over the past year, against +6.9% for the S&P 500.

How many NCEL shares are sold short?

0M shares were sold short at the latest FINRA report, 0.65% of the float, or 1.0 days of average trading volume.

Who are NewcelX's competitors?

Companies most similar to NewcelX by business, industry and size include CELU, LGVN, NBP, XTLB, OCS.

See a number that looks wrong?